Brief: FDA Lifts Clinical Hold On Nuz-001
06/10/2025 07:35
Oct 6 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX: FDA LIFTS CLINICAL HOLD ON NUZ-001 NEURIZON THERAPEUTICS LTD: CLEARS WAY FOR ENTRY INTO HEALEY ALS PLATFORM TRIAL EXPECTED TO COMMENCE IN Q4 CY2025 Source text: ID:nPn1R427xa Further company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO